Antineoplastics
1
Reactions 1252 - 16 May 2009 S Antineoplastics Fatal infections, and bleomycin-induced pneumonitis: 10 case reports In a retrospective study of patients with Hodgkin’s disease, 10 patients were identified, who developed severe treatment-related toxicity during antineoplastic therapy [dosages not stated]; six patients developed bleomycin- induced pneumonitis (BIP), three patients died of bacterial infections and one patient died of invasive aspergillosis. [See table for patient characteristics.] Patient characteristics Patient Sex/age (y) Antineoplastic ADR therapy 1 M/72 ABVD BIP 2 F/77 ABVD BIP 3 M/72 ABVD BIP 4 M/68 ABVD BIP 5 M/59 ABVD BIP 6 F/39 BEACOPPesc BIP 7 M/61 BEACOPPbas bacterial infection 8 F/50 BEACOPPesc bacterial infection 9 M/51 DHAP bacterial infection 10 M/39 BEACOPPesc invasive aspergillosis esc: escalated, bas: baseline The patients were treated according to the following protocols: ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine), BEACOPP (bleomycin, doxorubicin, etoposide, cyclophosphamide, vincristine, procarbazine and prednisone) or DHAP (dexamethasone, cytarabine and cisplatin); patients 3, 5 and 6 also received radiotherapy. BIP developed after 2–6 therapy cycles in patients 1–6 and was diagnosed according to clinical symptoms, and findings on chest CT and bronchoalveolar lavage. Treatment was discontinued in patients 1–3, 5 and 6; in patient 4, therapy was changed to a COPP protocol. All six patients received high-dose steroids and completely recovered. Patients 7–10 developed fatal infections after unspecified treatment durations. Patient 10 died of disseminated invasive Aspergillus fumigatus mycosis during first-line therapy, while the other three patients died of bacterial infections. Fong D, et al. Hodgkin lymphoma in Tyrol - a population-based study. Annals of Hematology 88: 449-456, No. 5, May 2009 - Austria 801141429 1 Reactions 16 May 2009 No. 1252 0114-9954/10/1252-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1252 - 16 May 2009
SAntineoplastics
Fatal infections, and bleomycin-inducedpneumonitis: 10 case reports
In a retrospective study of patients with Hodgkin’sdisease, 10 patients were identified, who developed severetreatment-related toxicity during antineoplastic therapy[dosages not stated]; six patients developed bleomycin-induced pneumonitis (BIP), three patients died of bacterialinfections and one patient died of invasive aspergillosis.[See table for patient characteristics.]
Patient characteristicsPatient Sex/age (y) Antineoplastic ADR
therapy
1 M/72 ABVD BIP2 F/77 ABVD BIP3 M/72 ABVD BIP4 M/68 ABVD BIP5 M/59 ABVD BIP6 F/39 BEACOPPesc BIP
7 M/61 BEACOPPbas bacterial infection8 F/50 BEACOPPesc bacterial infection9 M/51 DHAP bacterial infection10 M/39 BEACOPPesc invasive aspergillosis
esc: escalated, bas: baseline
The patients were treated according to the followingprotocols: ABVD (doxorubicin, bleomycin, vinblastine anddacarbazine), BEACOPP (bleomycin, doxorubicin,etoposide, cyclophosphamide, vincristine, procarbazineand prednisone) or DHAP (dexamethasone, cytarabine andcisplatin); patients 3, 5 and 6 also received radiotherapy.BIP developed after 2–6 therapy cycles in patients 1–6 andwas diagnosed according to clinical symptoms, andfindings on chest CT and bronchoalveolar lavage.Treatment was discontinued in patients 1–3, 5 and 6; inpatient 4, therapy was changed to a COPP protocol. All sixpatients received high-dose steroids and completelyrecovered.
Patients 7–10 developed fatal infections after unspecifiedtreatment durations. Patient 10 died of disseminatedinvasive Aspergillus fumigatus mycosis during first-linetherapy, while the other three patients died of bacterialinfections.Fong D, et al. Hodgkin lymphoma in Tyrol - a population-based study. Annals ofHematology 88: 449-456, No. 5, May 2009 - Austria 801141429
1
Reactions 16 May 2009 No. 12520114-9954/10/1252-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
